




Instance: composition-en-ffc23a76b4090b54b8bc958f8ff82cb2
InstanceOf: CompositionUvEpi
Title: "Composition for strimvelis Package Leaflet"
Description:  "Composition for strimvelis Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp98b6202d4f182ead30f71d465894861f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - strimvelis"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Strimvelis is and what it is used for </li>
<li>What you need to know before your child is given Strimvelis </li>
<li>How Strimvelis is given </li>
<li>Possible side effects </li>
<li>How to store Strimvelis </li>
<li>Contents of the pack and further information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What strimvelis is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What strimvelis is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Strimvelis is a type of medicine called a gene therapy. It is made specially for each patient. </p>
<p>Strimvelis is used in children to treat a serious condition called ADA-SCID (adenosine deaminase-severe 
combined immune deficiency). It is used when your child cannot receive a bone marrow transplant from a 
family donor because the match is not close enough. </p>
<p>ADA-SCID occurs because of a faulty gene in the blood cells of your child s immune system. As a result, 
the cells do not produce enough of an enzyme called adenosine deaminase (ADA) and your child s immune 
system does not work properly to defend the body against infections.  </p>
<p>To make Strimvelis, stem cells from your child s bone marrow are modified in the laboratory to insert a gene 
that produces ADA. When these modified stem cells are given back to your child, they can divide to produce 
different types of blood cells, including cells involved in your child s immune system.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take strimvelis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take strimvelis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Strimvelis is not suitable for some people </p>
<p>Strimvelis must not be given if your child:</p>
<ul>
<li>is allergic to any of the ingredients of this medicine (listed in section 6) </li>
<li>has or has had a type of cancer called leukaemia or myelodysplasia </li>
<li>has tested positive for HIV or some other infections (your doctor will advise you about this) </li>
<li>has already been treated with gene therapy </li>
</ul>
<p>Warnings and precautions  </p>
<p>Information about cell-based medicinal products, like Strimvelis, must be kept for 30 years at the hospital. 
The information kept about your child will be your child s name and the batch number of Strimvelis your 
child received. </p>
<p>Strimvelis is made specially from the patient s own cells. It must never be given to anyone else. </p>
<p>Inserting a new gene into the DNA could cause blood cancer. There has been a case of blood cancer, called 
leukaemia in one patient several years after treatment with Strimvelis. It is therefore important to monitor 
your child for the symptoms of leukaemia.<br />
These include fever, shortness of breath, paleness, night sweats, tiredness, swollen lymph glands, frequent 
infections, a tendency to bleed and/or bruise easily, or tiny red or purple spots under the skin. If your child 
develops any of these symptoms you should contact your doctor immediately.  </p>
<p>Before treatment with Strimvelis, your child will be given other medicines (see sections 3 and 4 for more 
information on these medicines, including possible side effects). </p>
<p>If your child has previously tested positive for hepatitis C, your child can still be treated under certain 
conditions. Your doctor will discuss this with you if needed. </p>
<p>Central venous catheters are thin, flexible tubes, that are inserted by a doctor into a large vein to access the 
bloodstream of your child. The risks of these lines are infections and the formation of blood clots. The doctor 
and nurses will monitor your child for any central venous catheter complications. </p>
<p>Treatment with Strimvelis has been unsuccessful in some patients. These patients received alternative 
treatment options.  </p>
<p>There is a small risk of infection as a result of the treatment. Your child s doctors and nurses will monitor 
them throughout the infusion for signs of infection and provide treatment if needed. </p>
<p>Some patients can develop autoimmunity i.e. trigger an immune response against their own cells or tissues 
(see section 4). Your child s doctor will discuss this with you if needed. </p>
<p>After the treatment, your child must not donate blood, organs, tissues or cells at any time in future. This is 
because Strimvelis is a gene therapy product.  </p>
<p>When Strimvelis treatment cannot be completed 
In some cases, it might not be possible to go ahead with the planned treatment with Strimvelis for reasons 
such as: 
* a problem taking the cells from your child s bone marrow to make the medicine 
* not enough of the right type of cells in the tissue taken from your child s body to make the medicine 
* the medicine not meeting all the quality tests<br />
* a delay in the medicine reaching the clinic where your child is being treated. </p>
<p>Before receiving Strimvelis your child will be given chemotherapy in order to remove their existing bone 
marrow. If Strimvelis cannot be administered after chemotherapy or if the modified stem cells do not take 
hold (engraft) in your child s body, the doctor will give your child replacement stem cells, using the backup 
sample that was collected and stored before treatment started (see also section 3, How Strimvelis is given). </p>
<p>You may need other treatment 
Strimvelis goes through a range of tests before it is used.  Because it is given soon after it is made, the final 
results of some of these tests will not be ready before the medicine is given. If the tests show anything that 
might affect your child, the doctor will treat your child as appropriate. </p>
<p>Other medicines and Strimvelis<br />
Tell your doctor if your child is taking, has recently taken or might take any other medicines.  </p>
<p>Your child must not be given vaccines called live vaccines for 6 weeks before they are given the 
conditioning medicine to prepare for Strimvelis treatment, nor after treatment while your child s immune 
system is recovering. </p>
<p>Strimvelis contains sodium 
This medicine contains 42 to 137 mg sodium (main component of cooking/table salt) in each dose. This is 
equivalent to 2 to 7% of the recommended maximum daily dietary intake of sodium for an adult. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take strimvelis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take strimvelis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Strimvelis is given by a drip (infusion) into a vein (intravenously). It must be given in a specialised hospital, 
and by a doctor who is experienced in treating patients with ADA-SCID and in using this type of medicine. </p>
<p>Before Strimvelis is made, the doctor will do tests to make sure that your child is not carrying certain 
infections (see section 2). </p>
<p>Two samples are collected 
The doctor will collect two samples of bone marrow cells before the planned treatment: 
* the backup sample, collected at least 3 weeks before Strimvelis treatment.  It will be stored, to be 
given as replacement cells if Strimvelis cannot be given or does not work (see  When Strimvelis 
treatment cannot be completed  in section 2) 
* the treatment sample, collected 4 to 5 days before Strimvelis treatment. It will be used to make 
Strimvelis, by inserting a new gene into the cells. </p>
<p>Before and during Strimvelis treatment </p>
<p>When 
What is done 
Why </p>
<p>At least 3 weeks before 
treatment </p>
<p>Backup sample of stem cells 
collected </p>
<p>to be stored as a backup (see 
above) </p>
<p>About 4 to 5 days before 
treatment </p>
<p>Treatment sample of stem cells 
collected </p>
<p>to make Strimvelis (see above) </p>
<p>3 days and 2 days before 
treatment </p>
<p>A medicine called busulfan is 
given 4 times a day for 2 days 
(total of 8 doses) </p>
<p>to prepare the bone marrow for 
Strimvelis treatment and clear 
existing stem cells </p>
<p>About 15 to 30 minutes 
before treatment </p>
<p>An antihistamine medicine may be 
given </p>
<p>to make it less likely that you will 
react to the infusion </p>
<p>Strimvelis is given<br />
by a drip into a vein. 
This will take about 20 minutes </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />
The side-effects linked to Strimvelis are caused by the immune system becoming over-active and attacking 
the body s own tissues. Some side effects may also be related to the busulfan medicine used to prepare your 
child s bone marrow for treatment; these are marked with an asterisk (*) in the list below. </p>
<p>Very common: may affect more than 1 in 10 people: 
* runny or blocked nose (allergic rhinitis) 
* wheezing, difficulty breathing (asthma) 
* inflamed itchy skin (atopic dermatitis, eczema) 
* raised temperature (pyrexia) 
* underactive thyroid gland (hypothyroidism) 
* high blood pressure (hypertension)<em> 
* decreases in the number of red or white blood cells (anaemia, neutropenia)</em> 
* increases in liver enzymes (which indicate stress on the liver)* 
     blood test results positive for antinuclear antibody and smooth muscle antibody (which might 
suggest possible autoimmunity) </p>
<p>Common: may affect up to 1 in 10 people.<br />
* red or purple dots on the skin, bleeding under the skin (autoimmune thrombocytopenia) 
* inflamed thyroid gland (autoimmune thyroiditis) 
* weakness and pain in the feet and hands caused by damage to nerves (Guillain-Barr  syndrome) 
* inflamed liver (autoimmune hepatitis) 
* reduced numbers of blood cells (autoimmune haemolytic anaemia, autoimmune aplastic anaemia) 
* blood test results positive for antineutrophil cytoplasmic antibody (which could lead to autoimmune 
inflammation and swelling of the blood vessels and possibly increased level of infections) 
* a type of blood cancer called leukaemia </p>
<p>If you have any questions about symptoms or side effects, or if any symptoms concern you, talk to your 
child s doctor or nurse. </p>
<p>Reporting of side effects 
If your child gets any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store strimvelis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store strimvelis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The following information is intended for doctors only. </p>
<p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date and time (EXP) which is stated on the container label and 
infusion bag label. </p>
<p>Store at 15 30  C. </p>
<p>This medicine contains genetically-modified human cells. Unused medicine or waste material must be 
disposed of in compliance with the local guidelines on handling human-derived material. As this medicine 
will be given by a qualified doctor, they are responsible for correct disposal of the product. These measures 
will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Strimvelis contains<br />
- The active substance is an autologous (the patient s own) CD34+ enriched cell fraction that contains 
CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence. The 
concentration is 1 10   106 CD34+ cells/mL. 
- The other ingredient is sodium chloride (see section 2,  Strimvelis contains sodium ). </p>
<p>What Strimvelis looks like and contents of the pack 
Strimvelis is a cloudy to clear, colourless to pink dispersion of cells for infusion, which is supplied in one or 
more infusion bags. The infusion bags are provided in a closed container. </p>
<p>Marketing Authorisation Holder<br />
Fondazione Telethon ETS 
Via Varese 16/B 
00185 Rome 
Italy  </p>
<p>Manufacturer 
AGC Biologics S.p.A. 
58 Via Olgettina 
20Milan 
ITALY </p>
<p>This leaflet was last revised in MM/YYYY. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-ffc23a76b4090b54b8bc958f8ff82cb2
InstanceOf: CompositionUvEpi
Title: "Composition for strimvelis Package Leaflet"
Description:  "Composition for strimvelis Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp98b6202d4f182ead30f71d465894861f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - strimvelis"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før dit barn får Strimvelis </li>
<li>Sådan gives Strimvelis </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What strimvelis is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What strimvelis is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Strimvelis er en type lægemiddel, som bruges til genterapi. Det fremstilles specielt til hver enkelt patient. </p>
<p>Strimvelis bruges hos børn til at behandle en alvorlig sygdom kaldet ADA-SCID (svær kombineret 
adenosindeaminase-immundefekt). Det bruges, når dit barn ikke kan få et knoglemarvstransplantat fra en 
donor i familien, da deres match ikke er god nok.  </p>
<p>ADA-SCID forårsages af et defekt gen i blodcellerne i dit barns immunsystem. Cellerne kan derfor ikke 
producere nok af et enzym, som kaldes adenosindeaminase (ADA), så dit barns immunsystem ikkefungerer, 
som det skal, og derfor ikke kan forsvare kroppen mod infektioner.  </p>
<p>Strimvelis fremstilles ved at modificere stamceller fra dit barns knoglemarv på laboratoriet ved at indføre et 
nyt gen, som producerer ADA. Når dit barn får disse modificerede stamceller igen, kan de dele sig og 
producere forskellige typer blodceller, herunder cellerne involveret i dit barns immunsystem. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take strimvelis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take strimvelis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Strimvelis er ikke egnet til visse personer </p>
<p>Dit barn må ikke få Strimvelis:</p>
<ul>
<li>hvis dit barn er allergisk over for nogen af indholdsstofferne (angivet i punkt 6) </li>
<li>hvis dit barn har eller har haft myelodysplasi eller en type cancer, som kaldes leukæmi  </li>
<li>hvis dit barn er testet positiv for hiv eller andre infektioner (din læge vil rådgive dig om dette) </li>
<li>hvis dit barn allerede er blevet behandlet med genterapi. </li>
</ul>
<p>Advarsler og forsigtighedsregler  </p>
<p>Information om cellebaserede produkter, såsom Strimvelis, skal gemmes på hospitalet i 30 år. De 
oplysninger, som gemmes om dit barn, vil være dit barns navn og det batchnummer af Strimvelis, som dit 
barn modtog.  </p>
<p>Strimvelis er fremstillet ud fra patientens egne celler. Lægemidlet må aldrig gives til andre. </p>
<p>Indsættelse af et nyt gen i DNA'et kan forårsageblodkræft. Der har været et tilfælde af blodkræft, kaldet 
leukæmi, hos én patient flere år efter behandling med Strimvelis. Det er derfor vigtigt, at du overvåger dit 
barn for symptomer på leukæmi. De kan inkludere feber, åndenød, bleghed, nattesved, træthed, hævede 
lymfekirtler, hyppige infektioner, blødningstendens eller let til at få blå mærker, eller små røde eller lilla 
pletter under huden. Hvis dit barn udvikler nogen af disse symptomer, skal du straks kontakte din læge. </p>
<p>Inden behandling med Strimvelis vil dit barn få andre lægemidler (se pkt. 3 og 4 for mere information om 
disse lægemidler, herunder mulige bivirkninger). </p>
<p>Hvis dit barn tidligere er testet positiv for hepatitis C, kan dit barn stadig behandles under visse 
omstændigheder. Din læge kan drøfte dette med dig efter behov. </p>
<p>Centrale venekatetre er tynde, fleksible slanger, som indføres af en læge i en stor vene hos dit barn for at få 
adgang til blodomløbet. Risiciene ved disse slanger er infektion og dannelsen af blodpropper. Lægerne og 
sygeplejerskerne vil overvåge dit barn for komplikationer relateret til det centrale venekateter. </p>
<p>Behandling med Strimvelis har ikke været vellykket hos nogle patienter. Disse patienter fik alternativ 
behandling.  </p>
<p>Der er en lille risiko for infektion som følge af behandlingen. Dit barns læger og sygeplejersker vil overvåge 
dit barn under infusionen for tegn på infektion og behandle dit barn, hvis der skulle blive behov for det. </p>
<p>Nogle patienter kan udvikle autoimmunitet, dvs. udløse en immunrespons mod deres egne celler eller væv 
(se afsnit 4). Dit barns læge vil drøfte dette med dig, hvis det skulle blive nødvendigt. 
Efter behandlingen  må dit barn ikke donere blod, organer eller væv på noget tidspunkt i fremtiden. Grunden 
til dette er, at Strimvelis er et genterapipræparat. </p>
<p>Når behandlingen med Strimvelis ikke kan gennemføres </p>
<p>I visse tilfælde vil det muligvis ikke kunne lade sig gøre at påbegynde den planlagte behandling med 
Strimvelis af grunde, som f.eks.: </p>
<ul>
<li>
<p>et problem med at udtage cellerne fra dit barns knoglemarv for at fremstille medicinen </p>
</li>
<li>
<p>ikke et tilstrækkeligt antal af den rette type celler i vævet udtaget fra dit barns krop til at fremstille 
medicinen </p>
</li>
<li>
<p>medicinen opfyldte ikke alle kvalitetstest </p>
</li>
<li>
<p>en forsinkelse under transporten af medicinen til det hospital, hvor dit barn bliver behandlet. </p>
</li>
</ul>
<p>Før dit barn får Strimvelis, vil det få kemoterapi for at fjerne den eksisterende knoglemarv. Hvis Strimvelis 
ikke kan administreres efter kemoterapi, eller hvis de modificerede stamceller ikke finder sig til rette 
(inkorporeres) i dit barns krop, vil lægen give dit barn erstatningsstamceller fra den reserveprøve, som blev 
taget og gemt, inden behandlingen startede (se også punkt 3, Sådan gives Strimvelis). </p>
<p>Du kan have brug for anden behandling 
Strimvelis underkastes en række tests, inden det bruges. Da lægemidlet indgives kort tid efter fremstillingen, 
vil de endelige resultater af nogle af disse tests ikke foreligge, før det gives. Hvis resultaterne af testene viser 
noget, som kan påvirke dit barn, vil lægen give dit barn en passende behandling. </p>
<p>Brug af anden medicin sammen med Strimvelis </p>
<p>Fortæl altid lægen, hvis dit barn tager, for nylig har taget anden medicin eller  planlægger at tage anden 
medicin. </p>
<p>Dit barn må ikke få vacciner, som kaldes levende vacciner, i 6 uger efter modtagelse af den konditionerende 
medicin, der gives som forberedelse på Strimvelis behandling, mens dit barns immunsystem kommer sig. </p>
<p>Strimvelis indeholder natrium </p>
<p>Dette lægemiddel indeholder 42 til 137 mg natrium (hovedkomponent af  madlavnings-/bordsalt) pr. dosis. 
Dette svarer til 2 til 7 % af den anbefalede maksimale daglige indtagelse af natrium for en voksen. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take strimvelis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take strimvelis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Strimvelis gives i et drop (infusion) i en vene (intravenøst). Det skal indgives på et specialiseret hospital af 
en læge, som har erfaring med behandling af patienter med ACA-SCID og med brug af denne type medicin. </p>
<p>Inden Strimvelis fremstilles, udfører lægen nogle tests for at sikre, at dit barn ikke har visse infektioner (se 
punkt 2). </p>
<p>Der indsamles to prøver 
Lægen udtager to prøver af celler fra knoglemarven inden den planlagte behandling: </p>
<ul>
<li>
<p>Reserveprøven, der tages mindst 3 uger før behandlingen med Strimvelis. Den gemmes, så den kan 
gives som erstatningsceller, hvis Strimvelis ikke kan gives eller ikke virker (se ‘Når behandlingen med 
Strimvelis ikke kan gennemføres’ i punkt 2). </p>
</li>
<li>
<p>Behandlingsprøven, der tages 4-5 dage før behandlingen med Strimvelis. Den bruges til at fremstille 
Strimvelis ved at indføre et nyt gen i cellerne. </p>
</li>
</ul>
<p>Før og under behandling med Strimvelis </p>
<p>Hvornår 
Hvad sker der 
Hvorfor </p>
<p>Mindst 3 uger før 
behandlingen </p>
<p>Reserveprøve af stamceller 
udtages </p>
<p>gemmes som reserve (se ovenfor) </p>
<p>Ca. 4-5 dage før 
behandlingen </p>
<p>Behandlingsprøve af stamceller 
udtages </p>
<p>til fremstilling af Strimvelis (se 
ovenfor) </p>
<p>3 dage og 2 dage før 
behandlingen </p>
<p>Et lægemiddel kaldet busulfan 
gives 4 gange dagligt i 2 dage 
(8 doser i alt) </p>
<p>for at klargøre knoglemarven til 
behandling med Strimvelis og 
rydde eksisterende stamceller </p>
<p>Ca. 15-30 minutter før 
behandlingen </p>
<p>Der kan gives et 
antihistaminpræparat </p>
<p>for at mindske risikoen for, at du 
får bivirkninger i forbindelse med 
infusionen </p>
<p>Strimvelis gives… 
i et drop i en vene. 
Det tager ca. 20 minutter </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Bivirkningerne forbundet med Strimvelis skyldes, at immunsystemet bliver overaktivt og angriber kroppens 
egne væv. Nogle bivirkninger kan desuden være relateret til busulfan lægemidlet, som anvendes til at 
klargøre dit barns knoglemarv til behandlingen; disse er markeret med en stjerne (*) i nedenstående liste. </p>
<p>Meget almindelige: Kan forekomme hos flere end 1 ud af 10 personer: </p>
<ul>
<li>
<p>løbende eller tilstoppet næse (allergisk rhinitis) </p>
</li>
<li>
<p>hvæsende vejrtrækning, vejrtrækningsbesvær (astma) </p>
</li>
<li>
<p>irriteret, kløende hud (eksem) </p>
</li>
<li>
<p>forhøjet temperatur </p>
</li>
<li>
<p>underaktiv skjoldbruskkirtel (lavt stofskifte) </p>
</li>
<li>
<p>forhøjet blodtryk (hypertension)* </p>
</li>
<li>
<p>nedsat antal røde eller hvide blodceller (anæmi, neutropeni)* </p>
</li>
<li>
<p>forhøjede leverenzymer (hvilket angiver stress for leveren)* </p>
</li>
<li>
<p>positive blodprøveresultater for antinukleære antistoffer og glat muskelatur-antistof (som kan angive 
mulig autoimmunitet) </p>
</li>
</ul>
<p>Almindelige: Kan forekomme hos op til 1 ud af 10 personer. </p>
<ul>
<li>
<p>røde eller lilla pletter på huden, blødning under huden (autoimmun trombocytopeni) </p>
</li>
<li>
<p>betændelseslignende reaktion (inflammation) i skjoldbruskkirtlen (autoimmun thyroiditis) </p>
</li>
<li>
<p>svaghed og smerter i fødder og hænder forårsaget af nerveskader (Guillain-Barré-syndrom) </p>
</li>
<li>
<p>leverbetændelse (autoimmun hepatitis) </p>
</li>
<li>
<p>nedsat antal blodceller (autoimmun hæmolytisk anæmi, autoimmun aplastisk anæmi) </p>
</li>
<li>
<p>positive blodprøveresultater for anti-neutrofilocyt cytoplasma-antistof (hvilket kan medføre 
autoimmun inflammation og hævelse af blodkarrene og muligvis øget infektionsniveau) </p>
</li>
<li>
<p>en type blodkræft kaldet leukæmi </p>
</li>
</ul>
<p>Hvis du har spørgsmål om symptomer eller bivirkninger, eller hvis du har symptomer, som bekymrer dig, 
kontakt dit barns læge eller sygeplejerske. </p>
<p>Indberetning af bivirkninger 
Hvis dit barn oplever bivirkninger, bør du tale med din læge eller sygeplejerske. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. 
Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af 
dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store strimvelis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store strimvelis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Følgende information er kun beregnet til læger. </p>
<p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato og det tidspunkt (EXP), som står på etiketten på beholderen og 
infusionsposen. </p>
<p>Opbevares ved 15-30 °C. </p>
<p>Denne medicin indeholder genmodificerede humane celler. Ikke anvendt lægemiddel samt affald heraf skal 
bortskaffes i henhold til lokale retningslinjer vedrørende håndtering af materiale, der stammer fra mennesker. 
Da dette lægemiddel indgives af en læge, er denne ansvarlig for korrekt bortskaffelse af præparatet. Af 
hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Strimvelis indeholder:</p>
<ul>
<li>Aktivt stof: en autolog CD34+-beriget cellefraktion, som indeholder CD34+-celler transduceret med 
retroviral vektor, som koder for den humane ADA-cDNA-sekvens. Koncentrationen er 1-10 × CD34+-celler/ml. Autolog betyder, at cellefraktionen stammer fra patienten selv. </li>
<li>Øvrige indholdsstoffer: natriumchlorid (se punkt 2, “Strimvelis indeholder natrium"). </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Strimvelis er en uklar til klar, farveløs til lyserød dispersion (opslæmning) af celler til infusion, som leveres i 
en eller flere infusionsposer. Infusionsposerne leveres i en lukket beholder. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Fondazione Telethon ETS 
Via Varese 16/B 
00185 Rome<br />
Italien </p>
<p>Fremstiller </p>
<p>AGC Biologics S.p.A. 
58 Via Olgettina 
20Milano 
Italien </p>
<p>Denne indlægsseddel blev senest ændret MM/ÅÅÅÅ. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere information om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme og om, 
hvordan de behandles.  </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs hjemmeside. </p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Sikkerhedsforanstaltninger, der skal tages før håndtering og administration af lægemidlet 
Sundhedspersoner, som håndterer Strimvelis, skal derfor tage passende forholdsregler (brug af handsker, 
beskyttelsesbeklædning og øjenværn) for at undgå potentiel overførsel af smitsomme sygdomme.  </p>
<p>Strimvelis transporteres direkte til det hospital, hvor infusionen skal gives. Infusionsposen er placeret i en 
lukket ydre beholder. Poserne skal opbevares i den ydre beholder indtil brug. </p>
<p>Strimvelis er alene beregnet til autolog brug. Inden infusion skal det sikres, at patientens identitet svarer til 
de unikke patientoplysninger på infusionsposen/-poserne og/eller den ydre beholder.  </p>
<p>Vend forsigtigt infusionsposen op og ned for at dispergere eventuelle celleaggregater og udfør infusionen 
med et transfusionssæt med filter for at fjerne eventuelle tilbageværende celleaggregater. </p>
<p>Regler for bortskaffelse af lægemidlet 
Lokale retningslinjer for håndtering af materiale, der stammer fra mennesker, skal følges for bortskaffelse af 
ikke anvendt lægemiddel samt affald heraf. Alt materiale, som har været i kontakt med Strimvelis (flydende 
og fast affald) skal håndteres og bortskaffes som potentielt infektiøst affald i henhold til lokale retningslinjer 
for håndtering af materiale, der stammer fra mennesker. </p>
<p>Utilsigtet eksponering 
Eksponering for Strimvelis ved et uheld skal undgås. Lokale retningslinjer for håndtering af materiale, der 
stammer fra mennesker, skal følges i tilfælde af utilsigtet eksponering, hvilket kan omfatte at skylle 
kontamineret hud og fjerne kontamineret beklædning. Arbejdsoverflader og materiale, som kan have været i 
kontakt med Strimvelis, skal dekontamineres med et passende desinfektionsmiddel. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-ffc23a76b4090b54b8bc958f8ff82cb2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for strimvelis Package Leaflet for language en"
Description: "ePI document Bundle for strimvelis Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-ffc23a76b4090b54b8bc958f8ff82cb2"
* entry[0].resource = composition-en-ffc23a76b4090b54b8bc958f8ff82cb2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpffc23a76b4090b54b8bc958f8ff82cb2"
* entry[=].resource = mpffc23a76b4090b54b8bc958f8ff82cb2
                            
                    
Instance: bundlepackageleaflet-da-ffc23a76b4090b54b8bc958f8ff82cb2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for strimvelis Package Leaflet for language da"
Description: "ePI document Bundle for strimvelis Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-ffc23a76b4090b54b8bc958f8ff82cb2"
* entry[0].resource = composition-da-ffc23a76b4090b54b8bc958f8ff82cb2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpffc23a76b4090b54b8bc958f8ff82cb2"
* entry[=].resource = mpffc23a76b4090b54b8bc958f8ff82cb2
                            
                    



Instance: mpffc23a76b4090b54b8bc958f8ff82cb2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Strimvelis 1-10 x 106 cells/mL dispersion for infusion"
Description: "Strimvelis 1-10 x 106 cells/mL dispersion for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/16/1097/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Strimvelis 1-10 x 106 cells/mL dispersion for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: ffc23a76b4090b54b8bc958f8ff82cb2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "strimvelis"

* status = #current
* mode = #working

* title = "List of all ePIs associated with strimvelis"

* subject = Reference(mp98b6202d4f182ead30f71d465894861f)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#strimvelis "strimvelis"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-ffc23a76b4090b54b8bc958f8ff82cb2) // strimvelis en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-ffc23a76b4090b54b8bc958f8ff82cb2) // strimvelis da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-ffc23a76b4090b54b8bc958f8ff82cb2
InstanceOf: List

* insert ffc23a76b4090b54b8bc958f8ff82cb2ListRuleset
    